Search

Background: Keloid and hypertrophic scars are pathological scars that occur as a result of the abnormal healing process of the skin against trauma. It bothers patients cosmetically and causes itching, pain, burning, sensitivity and loss of function in patients. There is no single treatment with proven efficacy in the treatment of keloid and hypertrophic scars. Laser treatments, a relatively new modality, are increasingly being used in keloid and hypertrophic scars treatment to reduce the risk of relapse and achieve positive cosmetic and symptomatic results. In our study, we aimed to compare the effectiveness of long-pulsed Nd-YAG laser and fractional Er-YAG laser treatments in the treatment of keloid and hypertrophic scars. Materials and Methods: Twenty patients with keloid and/or hypertrophic scars were included in the study. Patients with keloid and/or hypertrophic scars were divided into two groups of ten, each for five sessions of laser treatment. Group A received fractional Er: YAG laser, group B received long-pulsed Nd: YAG laser treatment. Patients were evaluated before treatment and their lesions were photographed. The patients were evaluated with the Stony Brook Scar Evaluation Scale and the treatment satisfaction scale three months after the treatment was completed. Results: There was no change in Stony Brook Scar Evaluation Scale scores before and after treatment in both groups. After the treatment, eight patients were satisfied with the treatment, and twelve patients were not satisfied with the treatment. Conclusion: Long-pulsed Nd-YAG laser and fractional Er-YAG laser treatments have not been shown to be effective in the treatment of keloid and/or hypertrophic scars. [ABSTRACT FROM AUTHOR]

Copyright of Van Tip Dergisi is the property of Yuzuncu Yil University, Faculty of Medicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introduction: Alopecia areata is an organ-specific autoimmune disease. In addition, treatment options are limited in pediatric patients. Topical immunotherapy treatment may be preferred, especially in pediatric patients with severe and/or refractory alopecia areata., Objectives: In this study, it was aimed to examine the effect of atopic dermatitis, which is one of the poor prognostic factors in pediatric alopecia areata, on topical immunotherapy treatment., Methods: The data of patients aged 18 years and younger who received at least 20 sessions of topical immunotherapy with the diagnosis of alopecia areata in our clinic between January 2018 and December 2020 were analyzed., Results: A total of 139 patients were included in the study. The mean age of the patients was 10.29 years, 67 (48.20%) of the patients were female, 72 (51.80%) were male, 24 (17.26%) of the patients had mild disease, 115 of them (82.73%) had severe disease. Atopic dermatitis accompanying alopecia areata was detected in 38 of the patients. Inadequate response was obtained in 60 (43.17%) patients and adequate response was obtained in 79 (56.83%) patients with topical immunotherapy treatment. In addition, the presence of atopic dermatitis in the patient group with inadequate response to treatment was found to be statistically significantly higher than the patient group with adequate response to treatment., Conclusions: Topical immunotherapy treatment was found to be effective in 56.83% of pediatric alopecia areata patients included in the study. Our study showed that questioning pediatric alopecia areata patients for atopic dermatitis before topical immunotherapy treatment can predict the response to treatment.